Moderna, Inc. (NASDAQ: MRNA) shares are swinging in volatile early trading on Friday, February 27, 2026, as investors digest ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

Moderna (MRNA) stock fell 9% premarket after FDA rejected its flu vaccine application due to trial design issues, despite finding no safety concerns with mRNA-1010.

Moderna (MRNA) stock closed higher on Wednesday after the FDA reversed its earlier refusal-to-file decision on the company’s ...

Moderna Inc MRNA shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 ...

The stock’s movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license ...

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors ...

Moderna (MRNA) closed at $41.95 in the latest trading session, marking a +2.29% move from the prior day. The stock's change ...

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.

Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% ...

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...